Accès gratuit
Numéro
Med Sci (Paris)
Volume 23, Numéro 5, Mai 2007
Page(s) 502 - 508
Section M/S revues
DOI https://doi.org/10.1051/medsci/2007235502
Publié en ligne 15 mai 2007
  1. Karre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319 : 675–8. [Google Scholar]
  2. Ahmad A, Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J Leuk Biol 2004; 76 : 743–59. [Google Scholar]
  3. Lanier LL. NK Cell Recognition. Annu Rev Immunol 2005; 23 : 225–74. [Google Scholar]
  4. Katz G, Gazit R, Arnon T, et al. MHC class I independent recognition of NK activating receptor KIR2DS4. J Immunol 2004; 173 : 1819–25. [Google Scholar]
  5. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94 : 333–9. [Google Scholar]
  6. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295 : 2097–100. [Google Scholar]
  7. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102 : 814–9. [Google Scholar]
  8. Ruggeri L, Mancusi A, Capanni M, et al. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005; 17 : 211–7. [Google Scholar]
  9. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med 1971; 135 : 1513–28. [Google Scholar]
  10. Ogasawara K, Benjamin J, Takai R, et al. A role for NKG2D in NK cell-mediated rejection of mouse bone marrow grafts. Nat Immunol 2005; 6 : 938–45. [Google Scholar]
  11. Lundqvist A, McCoy JP, Samsel L, et al. Reduction of GvHD and enhanced anti-tumor effects after adoptive infusion of alloreactive Ly49-mismatched NK-cells from MHC-matched donors. Blood 2007; 109 : 3603–6. [Google Scholar]
  12. Coupel S, Moreau N, Hamidou M, et al. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 2006; online 19 décembre. [Google Scholar]
  13. Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft versus host disease. Biol Blood Marrow Transpl 2003; 9 : 170–6. [Google Scholar]
  14. Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol 2004; 173 : 3653–9. [Google Scholar]
  15. Caligiuri MA, Velardi A, Scheinberg DA, et al. Immunotherapeutic approaches for hematologic malignancies. Hematology 2004; 337–53. [Google Scholar]
  16. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105 : 4878–84. [Google Scholar]
  17. Schaffer M, Malmberg KT, Ringden O, et al. Increased infection-related mortality in KIR ligand mismatched unrelated allogeneic transplantation in AML. Transplantation 2004; 78 : 1081–5. [Google Scholar]
  18. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002; 100 : 3825–7. [Google Scholar]
  19. Giebel S, Nowak I, Wojnar J, et al. Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation. Transplant Proc 2006; 38 : 287–91. [Google Scholar]
  20. Verheyden S, Scots S, Duguet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemia relapses after related identical hematopoietic stem cell transplantation. Leukemia 2005; 19 : 1446–51. [Google Scholar]
  21. Kroger N, Binder T, Zabelina T, et al. Low number of donor activating killer immunoglobulin-like receptor (KIR) genes but not KIR-ligand mismatch prevents relapses and improves disease-free survival in leukemia patients after in vivo T cell-depleted unrelated stem cell transplantation. Transplantation 2006; 82 : 1024–30. [Google Scholar]
  22. Albertsson PA, Basse PH, Hokland M, et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 2003; 24 : 603–9. [Google Scholar]
  23. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88 : 577–83. [Google Scholar]
  24. Lee SG, Heo DS, Yoon S, et al. Effect of GM-CSF and IL-2 co-expression on anti-tumor immune response. Anticancer Res 2000; 20 : 2681–6. [Google Scholar]
  25. Son YI, Dallal RM, Mailliard RB, et al. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res 2001; 61 : 884–8. [Google Scholar]
  26. Salih HR, Antropius A, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102 : 1389–96. [Google Scholar]
  27. Fauriat C, Just-Landi S, Mallet F. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemic cells in NCR dull phenotype induction. Blood 2007; 109 : 323–30. [Google Scholar]
  28. Demanet C, Moulder A, Denevers A. Downregulation of HLA-A and HLA-Bw6, but not HLA-Bw4 allospecificities, in leukemia cells: an escape mechanism from CTL and NK attack ? Blood 2004; 15 : 3122–30. [Google Scholar]
  29. Bukur J, Rebmann V, Gross-Wilde H, et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003; 63 : 4107–11. [Google Scholar]
  30. Tripathy P, Agarwal S. Non classical HLA-G antigen and its role in the cancer progression. Cancer Invest 2006; 24 : 178–86. [Google Scholar]
  31. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005; 106 : 376–83. [Google Scholar]
  32. Koh CY, Blazar BR, George T, et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001; 97 : 3132–7. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.